ORMP - Oramed Pharmaceuticals Inc.

NasdaqCM - NasdaqCM Delayed Price. Currency in USD
4.0400
-0.0400 (-0.98%)
As of 1:47PM EST. Market open.
Stock chart is not supported by your current browser
Previous Close4.0800
Open4.0900
Bid4.01 x 800
Ask4.04 x 900
Day's Range4.0000 - 4.1400
52 Week Range3.9100 - 9.4800
Volume16,691
Avg. Volume24,834
Market Cap70.209M
Beta (3Y Monthly)0.67
PE Ratio (TTM)N/A
EPS (TTM)-0.86
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est15.00
Trade prices are not sourced from all markets
  • Is Oramed Pharmaceuticals Inc’s (NASDAQ:ORMP) CEO Paid Enough Relative To Peers?
    Simply Wall St.14 days ago

    Is Oramed Pharmaceuticals Inc’s (NASDAQ:ORMP) CEO Paid Enough Relative To Peers?

    Nadav Kidron has been the CEO of Oramed Pharmaceuticals Inc (NASDAQ:ORMP) since 2006. First, this article will compare CEO compensation with compensation at similar sized companies. Next, we’ll consider growth Read More...

  • Zacks Small Cap Research26 days ago

    ORMP: Transferring Coverage; Multiple Clinical Readouts for Oral Protein Delivery Technology Over Next 12-18 Months

    Oramed Pharmaceuticals Inc. (ORMP) is a biotechnology company with a proprietary oral protein delivery platform technology. The lead development candidate is ORMD-0801, an oral insulin, that is currently being tested in both type 1 (T1D) and type 2 diabetics (T2D). The clamp study is enrolling T1D patients with HbA1c levels ≤ 10% between the ages of 18-70 The clamp study was originally developed in 1979 as a means of testing how well a patient metabolizes glucose and their insulin sensitivity (DeFronzo et al., 1979).

  • Oramed Completes Over 50% Randomization in Its Pivotal 90-Day Clinical Study
    PR Newswire28 days ago

    Oramed Completes Over 50% Randomization in Its Pivotal 90-Day Clinical Study

    NEW YORK, Nov. 13, 2018 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (ORMP) (ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, announced today that it has successfully randomized more than 50% of the expected 285 patients for its 90-day dose-ranging Pivotal Phase 2b clinical study of its oral insulin capsule, ORMD-0801. "We are pleased that the pace of patient enrollment is in line with our expectations and look forward to data release in the coming year," stated Oramed CEO, Nadav Kidron. Oramed Pharmaceuticals is a platform technology pioneer in the field of oral delivery solutions for drugs currently delivered via injection.

  • Oramed to Present at the Tides Europe 2018 Conference
    PR Newswirelast month

    Oramed to Present at the Tides Europe 2018 Conference

    NEW YORK, Nov. 5, 2018 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (ORMP) (ORMP) (www.oramed.com),  a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, announced today that the Company will participate in the upcoming Tides Europe 2018 Conference, EuroPeptides Track, taking place on November 6-9, 2018 in Amsterdam.  Dr. Miriam Kidron, Oramed's Chief Scientific Officer, will speak about "Oral Insulin: An Impending Reality?" at the conference on November 7, 2018. Oramed Pharmaceuticals is a technology pioneer in the field of oral delivery solutions for drugs currently delivered via injection. Established in 2006, Oramed's Protein Oral Delivery (PODTM) technology is based on over 30 years of research by top scientists at Jerusalem's Hadassah Medical Center.

  • Oramed to Present at Cardiometabolic Health Congress
    PR Newswire2 months ago

    Oramed to Present at Cardiometabolic Health Congress

    Now in its 13th year, the Cardiometabolic Health Congress is the largest, US-based, multidisciplinary conference focused solely on the management of cardiometabolic risk and the prevention of cardiovascular and metabolic disease. Oramed Pharmaceuticals is a platform technology pioneer in the field of oral delivery solutions for drugs currently delivered via injection. Established in 2006, Oramed's Protein Oral Delivery (PODTM) technology is based on over 30 years of research by scientists at Jerusalem's Hadassah Medical Center.

  • Oramed Enrolls First Patient in Its Clinical Study for Oral Insulin in the Treatment of NASH
    PR Newswire2 months ago

    Oramed Enrolls First Patient in Its Clinical Study for Oral Insulin in the Treatment of NASH

    NEW YORK, Oct. 4, 2018 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (ORMP) (ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, announced today it has enrolled the first patient in an exploratory clinical study of its oral insulin capsule, ORMD-0801, in the treatment of nonalcoholic steatohepatitis (NASH). The three-month treatment study, recently approved by Israel's Ministry of Health, will assess the effectiveness of ORMD-0801 in reducing liver fat content, inflammation and fibrosis in patients with NASH. Data from preclinical studies and clinical studies of ORMD-0801 demonstrate Oramed's oral insulin capsule has the potential to reduce inflammation of the liver.

  • Is Oramed Pharmaceuticals Inc’s (NASDAQ:ORMP) Balance Sheet Strong Enough To Weather A Storm?
    Simply Wall St.3 months ago

    Is Oramed Pharmaceuticals Inc’s (NASDAQ:ORMP) Balance Sheet Strong Enough To Weather A Storm?

    The direct benefit for Oramed Pharmaceuticals Inc (NASDAQ:ORMP), which sports a zero-debt capital structure, to include debt in its capital structure is the reduced cost of capital. However, the trade-offRead More...

  • Oramed Receives FDA Clearance for IND Application for Its Oral GLP-1 Analog Capsule
    PR Newswire3 months ago

    Oramed Receives FDA Clearance for IND Application for Its Oral GLP-1 Analog Capsule

    NEW YORK, Sept. 17, 2018 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (ORMP) (ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, announced today that the U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND) application for human trials of its oral GLP-1 analog capsule ORMD-0901. In a prior Phase 1 study on type 2 diabetic patients, Oramed's ORMD-0901 capsule was well tolerated and showed encouraging efficacy, including reducing blood sugar levels following a standard meal as compared to a placebo. Oramed's planned Phase 1 pharmacokinetic (PK) study is a fully-randomized, single-blind, placebo-controlled 4-way crossover study which will evaluate safety in addition to the pharmacokinetics of ORMD-0901 compared to placebo and to open label Byetta®, a GLP-1 analog currently on the market, in up to 15 healthy subjects.

  • Oramed to Present at the H.C. Wainwright Global Investment Conference
    PR Newswire3 months ago

    Oramed to Present at the H.C. Wainwright Global Investment Conference

    NEW YORK, Aug. 28, 2018 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (ORMP) (ORMP) (www.oramed.com),  a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, announced today that the Company will participate in the upcoming H.C. Wainwright 20th Annual Global Investment Conference, taking place September 4-6, 2018 in New York City.  Nadav Kidron, Oramed's CEO, will present a corporate overview at the conference on September 5, 2018.

  • Oramed Granted Japanese Patent for GLP-1 Analog Capsule
    PR Newswire5 months ago

    Oramed Granted Japanese Patent for GLP-1 Analog Capsule

    NEW YORK, July 24, 2018 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (ORMP) (ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, announced today that the Japanese Intellectual Property Office has publicized its intent to grant Oramed a patent titled, "Methods and Compositions for Oral Administration of Exenatide." The patent covers Oramed's proprietary invention of an oral glucagon-like peptide-1 (GLP-1) analog. Oramed Pharmaceuticals is a technology pioneer in the field of oral delivery solutions for drugs currently delivered via injection. Established in 2006, Oramed's Protein Oral Delivery (PODTM) technology is based on over 30 years of research by top scientists at Jerusalem's Hadassah Medical Center.

  • Benzinga5 months ago

    Benzinga's Daily Biotech Pulse: Bellicum CFO Resigns, Roche's Trial Meets Endpoints, Avid Bioservices Turns To Black In Q4

    Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling the Peaks (Stocks hitting 52-week highs on July 16) Arcus Biosciences Inc (NYSE: RCUS ) BioLife Solutions Inc (NASDAQ: ...

  • Associated Press5 months ago

    Oramed: Fiscal 3Q Earnings Snapshot

    The Jerusalem-based company said it had a loss of 30 cents per share. The results fell short of Wall Street expectations. The average estimate of three analysts surveyed by Zacks Investment Research was ...

  • PR Newswire5 months ago

    Oramed Announces Closing of $18.1 Million Registered Direct Offering

    NEW YORK, July 6, 2018 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (ORMP) (ORMP), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, announced today the closing of its previously-announced registered direct offering with several healthcare-focused institutional investors. Oramed has sold $18.1 million of shares of common stock and warrants to purchase shares of common stock at a combined price of $6.25 per share and related warrant. The securities described above were offered pursuant to a shelf registration statement (File No. 333-215525), which was declared effective by the United States Securities and Exchange Commission ("SEC") on February 2, 2017.

  • Oramed Announces $18.1 Million Registered Direct Offering
    PR Newswire5 months ago

    Oramed Announces $18.1 Million Registered Direct Offering

    NEW YORK, July 3, 2018 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (ORMP) (ORMP), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, announced today that it has entered into definitive agreements with several healthcare-focused institutional investors for the purchase in a registered direct offering of 2,892,000 shares of its common stock and warrants to purchase up to 2,892,000 shares of its common stock, at a combined purchase price of $6.25 per share and related warrants. The warrants have an exercise price of $7.25 per share of common stock, will be exercisable commencing six months following issuance and will expire three and one-half years from the issuance date. Oramed intends to use the net proceeds from this offering for expenses related to research and product development activities, clinical trial activities and for working capital and other general corporate purposes.

  • PR Newswire6 months ago

    Oramed Enrolls First Patient in Its Glucose Clamp Study for Oral Insulin

    NEW YORK, June 25, 2018 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (ORMP) (ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, announced today it has enrolled the first patient in its Glucose Clamp Study which will quantify insulin absorption in type 1 diabetes patients treated with its oral insulin capsule, ORMD-0801. The glucose clamp is a method for quantifying insulin absorption in order to measure a patient's insulin sensitivity and how well a patient metabolizes glucose. The glucose clamp technique represents the premier standard for pharmacodynamic studies in diabetes drug development and is a requirement of the FDA.

  • Oramed Initiates Food Effect Study for Its Oral Insulin Capsule ORMD-0801
    PR Newswire6 months ago

    Oramed Initiates Food Effect Study for Its Oral Insulin Capsule ORMD-0801

    NEW YORK, June 21, 2018 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (ORMP) (ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, announced today that it has initiated a food effect study in the U.S. for its oral insulin capsule ORMD-0801. The food effect study is a single blind, five period, randomized, placebo-controlled crossover study to evaluate the pharmacokinetics and pharmacodynamics of ORMD-0801 taken at different times in relation to meals in healthy volunteers and subjects with type 1 diabetes. Up to 48 subjects will be enrolled including 24 healthy volunteers and 24 subjects with type 1 diabetes.

  • Oramed to be Added to Russell Microcap® Index
    PR Newswire6 months ago

    Oramed to be Added to Russell Microcap® Index

    NEW YORK, June 19, 2018 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (ORMP) (ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, announced today that it will be added to the FTSE Russell Microcap® Index effective at the open of market on June 25, 2018, as part of the Russell Indexes annual reconstitution. Membership in the Russell Microcap® Index, which remains in place for one year, means automatic inclusion in the applicable growth and value style indexes. "We are pleased that Oramed has been selected for inclusion in the Russell Microcap® Index.

  • Oramed to Present at the American Diabetes Association 78th Scientific Sessions
    PR Newswire6 months ago

    Oramed to Present at the American Diabetes Association 78th Scientific Sessions

    NEW YORK , June 12, 2018 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (NASDAQ: ORMP) (TASE: ORMP) ( www.oramed.com ), a clinical-stage pharmaceutical company focused on the development of oral drug delivery ...

  • Oramed Patent Allowed in the US for Oral Administration of Proteins
    PR Newswire6 months ago

    Oramed Patent Allowed in the US for Oral Administration of Proteins

    NEW YORK, May 30, 2018 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (ORMP) (ORMP) (www.oramed.com), a developer of oral drug delivery systems, announced today that the Company's patent for its invention, titled "Methods and Compositions for Oral Administrations of Proteins," has been allowed by the United States Patent and Trademark Office. Oramed Pharmaceuticals is a technology pioneer in the field of oral delivery solutions for drugs currently delivered via injection. Established in 2006, Oramed's Protein Oral Delivery (POD™) technology is based on over 30 years of research by top scientists at Jerusalem's Hadassah Medical Center.

  • Market Exclusive7 months ago

    For Diabetes Patients, Management Solutions Are As Critical As Medications

    For diabetes sufferers, it’s not just effective medications that are necessary, but effective self-management. The challenge with diabetes, both type 1 and type 2, is not necessarily that the medications we have available today are just not good enough. The problem is, the disease has to be managed constantly, from the moment you wake up […] The post For Diabetes Patients, Management Solutions Are As Critical As Medications appeared first on Market Exclusive.

  • Oramed to Present at Conferences in May
    PR Newswire7 months ago

    Oramed to Present at Conferences in May

    NEW YORK , May 7, 2018 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (NASDAQ: ORMP) (TASE: ORMP) ( www.oramed.com ), a clinical-stage pharmaceutical company focused on the development of oral drug delivery ...

  • Oramed Initiates Its 90-Day Pivotal Dose-Ranging Clinical Study for Oral Insulin
    PR Newswire8 months ago

    Oramed Initiates Its 90-Day Pivotal Dose-Ranging Clinical Study for Oral Insulin

    NEW YORK, April 23, 2018 /PRNewswire/ --  Oramed Pharmaceuticals Inc. (ORMP) (ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, announced today it has begun screening patients in its 90-day dose-ranging Pivotal Phase 2b HbA1c clinical study of its oral insulin capsule, ORMD-0801. A statistically significant improvement in HbA1c (glycated hemoglobin), a long-term gauge of blood glucose control, was observed in just 28 days of treatment with ORMD-0801 in Oramed's prior Phase 2 study. The study will enroll approximately 240 patients with type 2 diabetes in multiple centers throughout the U.S. The primary end points are safety evaluating adverse and hypoglycemic events, and efficacy specific to HbA1c levels over 90 days of treatment.

  • Oramed to Present at H.C. Wainwright Annual Global Life Sciences Conference
    PR Newswire9 months ago

    Oramed to Present at H.C. Wainwright Annual Global Life Sciences Conference

    NEW YORK, March 27, 2018 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (ORMP) (ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, today announced it will be featured as a presenting company at the H. C. Wainwright Annual Global Life Sciences Conference. The conference is being held on April 8-10 at the Le Meridien Beach Plaza Hotel in Monte Carlo, Monaco. Oramed Pharmaceuticals is a technology pioneer in the field of oral delivery solutions for drugs currently delivered via injection. Established in 2006, Oramed's Protein Oral Delivery (PODTM) technology is based on over 30 years of research by top scientists at Jerusalem's Hadassah Medical Center.

  • Oramed to Present at Oppenheimer's Annual Healthcare Conference
    PR Newswire9 months ago

    Oramed to Present at Oppenheimer's Annual Healthcare Conference

    NEW YORK, March 15, 2018 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (NASDAQ/TASE: ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, announced today that the Company will participate in the upcoming Oppenheimer's 28th Annual Healthcare Conference, being held March 20-21, 2018 at the Westin New York Grand Central in New York City. Nadav Kidron, Chief Executive Officer of Oramed, will present a corporate overview on Wednesday, March 21, 2018.

  • PR Newswire9 months ago

    Oramed Adds Two New Members to its Scientific Advisory Board

    NEW YORK, Feb. 28, 2018  /PRNewswire/ -- Oramed Pharmaceuticals Inc. (ORMP) (ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, announced today the additions of Drs. Robert Henry and Jane Reusch to its Scientific Advisory Board. Dr. Henry is a leader in diabetes research. As a past President of the American Diabetes Association (ADA) and recipient of its Banting Medal for Scientific Achievement, among other international recognitions, his basic and clinical research funded by the National Institutes of Health (NIH) has resulted in more than 400 journal articles, chapters and books.